FELIX GALLEGOS, CAMILO EDGAR VINICIO

Preferred name

Main Affiliation

Facultad de Ciencias de la Salud Eugenio Espejo

CENIEC - Grupo de Investigación de Enfermedades Crónicas

Web Site

Google Scholar

ORCID

0000-0003-0224-2321

Scopus Author ID

57210396829

Now showing 1 - 10 of 23

Some of the metrics are blocked by your
consent settings
Self-Reported Prevalence of Chronic Non-Communicable Diseases Concerning Socioeconomic and Educational Factors: Analysis of the PURE-Ecuador Cohort
(Ubiquity Press, Ltd., 2025-03-13)
FELIX GALLEGOS, CAMILO EDGAR VINICIO
;
LOPEZ FLECHER, MAVEL ESTEFANIA
;
Michelle Vega
;
Katherine Andrango
;
Selena Andrango
Background: The changing epidemiological landscape, marked by the increasing prominence of Non-Communicable Chronic Diseases (NCDs), underscores the need for studies that identify and analyze these conditions and their associated risk factors. This secondary analysis aims to describe the association between socioeconomic and educational characteristics and the prevalence of self-reported NCDs among participants in the PURE-Ecuador cohort in urban and rural populations of the Metropolitan District of Quito (MDQ), Ecuador. Methods: This secondary analysis is part of the Prospective Urban Rural Epidemiological (PURE) study. Data were collected from February to December 2018, including 2028 participants aged 35 to 70 years from different urban and rural areas of the MDQ. Data collection utilized standardized questionnaires administered in face-to-face interviews. Pearson’s chi-square tests and multivariate logistic regression were used to assess associations. Results: The self-reported prevalence of hypertension was 16.2%, rising to 32.7% in individuals over 60 years old. The prevalence of diabetes mellitus was 6.7%, coronary heart disease 1.3%, stroke 1.6%, heart failure 1.3%, COPD 0.4%, asthma 1.3%, and cancer 1.9%. Multimorbidity affected 5.9% of participants, with the highest rates in obese and older individuals (≥60 years). Adherence to medications was high for hypertension and diabetes mellitus but varied substantially between communities. Conclusions: The secondary analysis revealed significant disparities in the prevalence and management of NCDs in MDQ. The prevalence of self-reported NCDs in Quito, Ecuador, is significantly associated with age and body mass index (BMI). Older individuals, particularly those over 60 years, and obese participants demonstrated higher rates of NCDs and multimorbidity. While socioeconomic factors such as education and income showed some associations with NCD prevalence, these were less pronounced after adjusting for other variables. These findings highlight the importance of age-specific and obesity-focused interventions in addressing the burden of NCDs in this population.
Scopus© Citations 3
Some of the metrics are blocked by your
consent settings
Heart Failure Among 173,000 Community-Dwelling Participants From 25 Low-, Middle-, and High-Income Countries in the PURE Study
(Elsevier BV, 2026-06)
Johansson Bartolini, Isabelle
;
Joseph, Philip
;
Islam, Shofiqul
;
Ramachan, Shameena P.
;
Rosengren, Annika
Scopus© Citations 4
Some of the metrics are blocked by your
consent settings
Effects of an Educational Comic Book on Knowledge, Attitudes, and Practices Regarding Epilepsy among Adolescents in Quito, Ecuador
(S. Karger AG, 2026-02-05)
Erazo, Daniells
;
FELIX GALLEGOS, CAMILO EDGAR VINICIO
;
LÓPEZ FLECHER, MAVEL ESTEFANÍA
;
Altayyar, Sarah
;
Gellé, Thibaut
Some of the metrics are blocked by your
consent settings
Rationale, Design and Baseline Characteristics of Participants in the C ardiovascular O utco m es for P eople Using A nticoagulation S trategie s (COMPASS) Trial
(Elsevier BV, 2017-08)
Jackie Bosch
;
John W. Eikelboom
;
Stuart J. Connolly
;
Nancy Cook Bruns
;
Vivian Lanius
Scopus© Citations 169
Some of the metrics are blocked by your
consent settings
Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial
(Oxford University Press (OUP), 2022-04-06)
John W Eikelboom
;
Jacqueline Bosch
;
Stuart J Connolly
;
Jessica Tyrwitt
;
Keith A A Fox
<jats:title>Abstract</jats:title> <jats:sec> <jats:title>Aims</jats:title> <jats:p>To describe outcomes of patients with chronic coronary artery disease (CAD) and/or peripheral artery disease (PAD) enrolled in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) randomized trial who were treated with the combination of rivaroxaban 2.5 mg twice daily and aspirin 100 mg once daily during long-term open-label extension (LTOLE).</jats:p> </jats:sec> <jats:sec> <jats:title>Methods and results</jats:title> <jats:p>Of the 27 395 patients enrolled in COMPASS, 12 964 (mean age at baseline 67.2 years) from 455 sites in 32 countries were enrolled in LTOLE and treated with the combination of rivaroxaban and aspirin for a median of 374 additional days (range 1–1191 days). During LTOLE, the incident events per 100 patient years were as follows: for the primary outcome [cardiovascular death, stroke, or myocardial infarction (MI)] 2.35 [95% confidence interval (CI) 2.11–2.61], mortality 1.87 (1.65–2.10), stroke 0.62 (0.50–0.76), and MI 1.02 (0.86–1.19), with CIs that overlapped those seen during the randomized treatment phase with the combination of rivaroxaban and aspirin. The incidence rates for major and minor bleeding were 1.01 (0.86–1.19) and 2.49 (2.24–2.75), compared with 1.67 (1.48–1.87) and 5.11 (95% CI 4.77–5.47), respectively, during the randomized treatment phase with the combination.</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusion</jats:title> <jats:p>In patients with chronic CAD and/or PAD, extended combination treatment for a median of 1 year and a maximum of 3 years was associated with incidence rates for efficacy and bleeding that were similar to or lower than those seen during the randomized treatment phase, without any new safety signals.</jats:p> </jats:sec>
Scopus© Citations 24
Some of the metrics are blocked by your
consent settings
Colchicine and aspirin in community patients with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial
(Elsevier BV, 2022-12)
John W Eikelboom
;
Sanjit S Jolly
;
Emilie P Belley-Cote
;
Richard P Whitlock
;
Sumathy Rangarajan
Scopus© Citations 27
Some of the metrics are blocked by your
consent settings
The Anti-Coronavirus Therapies (ACT) Trials: Design, Baseline Characteristics, and Challenges
(Elsevier BV, 2022-06)
John Eikelboom
;
Sumathy Rangarajan
;
Sanjit S. Jolly
;
Emilie P. Belley-Cote
;
Richard Whitlock
Scopus© Citations 8
Some of the metrics are blocked by your
consent settings
Obesity and Preeclampsia: Common Pathophysiological Mechanisms
(Frontiers Media SA, 2018-12-19)
LOPEZ JARAMILLO, JOSÉ PATRICIO
;
Juan Barajas
;
Sandra M. Rueda-Quijano
;
Cristina Lopez-Lopez
;
FELIX GALLEGOS, CAMILO EDGAR VINICIO
Scopus© Citations 166
Some of the metrics are blocked by your
consent settings
Mortality Benefit of Rivaroxaban Plus Aspirin in Patients With Chronic Coronary or Peripheral Artery Disease
(Elsevier BV, 2021-07)
John W. Eikelboom
;
Deepak L. Bhatt
;
Keith A.A. Fox
;
Jacqueline Bosch
;
Stuart J. Connolly
Scopus© Citations 59
Some of the metrics are blocked by your
consent settings
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease
(Massachusetts Medical Society, 2017-10-05)
John W. Eikelboom
;
Stuart J. Connolly
;
Jackie Bosch
;
Gilles R. Dagenais
;
Robert G. Hart
Scopus© Citations 2308

FELIX GALLEGOS, CAMILO EDGAR VINICIO

Filters

Settings

Sort By

Results per page